Abstract | OBJECTIVE: METHODS: Experimental CNV was induced in male cynomolgus monkeys by laser photocoagulation. Intravitreal injection of bevacizumab at 0.5 mg/eye/dosing was initiated 2 weeks before or after laser irradiation and thereafter, conducted intermittently at 2- or 3-week intervals. Fluorescein fundus angiography (FA) and OCT imaging were conducted weekly from 2 to 7 weeks after laser irradiation. CNV leakage was evaluated by an established grading method using FA images. To assess the fibrosis and scarring, Masson's trichrome specimens of each CNV lesion were prepared, and morphometric analysis was conducted using an image analysis software. RESULTS: The effects of bevacizumab on vascular leakage were shown using an established evaluation method. Morphometric analysis of Masson's trichrome-stained (MT) specimens revealed that collagen fiber synthesis was suppressed by bevacizumab pre-treatment (-29.2%) or post-treatment (-19.2%). SHRM was detected in OCT images in a monkey CNV model, and a significant correlation between the SHRM area in the OCT images and the collagen fiber area in the MT specimens was noted. CONCLUSION: In the established cynomolgus monkey CNV model, bevacizumab prevented blood leakage but could not completely suppress fibrosis. SHRM in the OCT images reflected retinal fibrous tissue in a laser-induced CNV monkey model. This model might be useful for elucidating the pathology and development therapy for neovascularization or fibrosis.
|
Authors | Satoshi Inagaki, Masamitsu Shimazawa, Koji Hamaguchi, Wataru Otsu, Tomoaki Araki, Yuji Sasaki, Yosuke Numata, Hideshi Tsusaki, Hideaki Hara |
Journal | Current neurovascular research
(Curr Neurovasc Res)
Vol. 17
Issue 4
Pg. 420-428
( 2020)
ISSN: 1875-5739 [Electronic] United Arab Emirates |
PMID | 32445455
(Publication Type: Journal Article)
|
Copyright | Copyright© Bentham Science Publishers; For any queries, please email at [email protected]. |
Chemical References |
- Angiogenesis Inhibitors
- Vascular Endothelial Growth Factor A
- Bevacizumab
|
Topics |
- Angiogenesis Inhibitors
(administration & dosage)
- Animals
- Bevacizumab
(administration & dosage)
- Choroidal Neovascularization
(diagnostic imaging, drug therapy, metabolism)
- Fibrosis
- Intravitreal Injections
(methods)
- Macaca fascicularis
- Male
- Retina
(diagnostic imaging, drug effects, metabolism)
- Tomography, Optical Coherence
(methods)
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors, metabolism)
|